NCT04108468View on ClinicalTrials.gov

GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA)

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Psoriatic Arthritis
Interventions
DRUG

Golimumab

Simponi

DRUG

Methotrexate

Methotrexate

Trial Locations (1)

LS7 4SA

The Leeds Teaching Hospitals NHS Trust, Leeds

All Listed Sponsors
collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

lead

The Leeds Teaching Hospitals NHS Trust

OTHER

NCT04108468 - GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA) | Biotech Hunter | Biotech Hunter